E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The mainstay of asthma treatment worldwide are β2-agonists and steroids. Current management of childhood acute asthma is based on British Thoracic Society guidelines, which recommend IVS as second line treatment. Whilst IVS can be highly effective in reversing bronchospasm, the overall evidence for this recommendation is week and predominantly comes from a single study. IVS has also been associated with side effects such as arrhythmias, lactic acidosis and diastolic hypotension. |
|
E.1.1.1 | Medical condition in easily understood language |
Every 18 minutes, a child is admitted to hospital with an acute asthma attack. Salbutamol is the main treatment and has saved countless lives. However, current dosages lead to frequent side effects |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
We wish to determine the best way to use a crucial drug called salbutamol in children with life-threatening asthma. We wish to analyse how the dose of salbutamol relates to its blood concentration level; and how the blood concentration level relates to effectiveness and toxicity.
This study will allow us develop a population pharmacokinetic-pharmacodynamics (PKPD) model of salbutamol in children. This will enable us to determine the optimal dose of salbutamol; to maximise its effectiveness but minimise harmful side effects.
|
|
E.2.2 | Secondary objectives of the trial |
We will also explore if there are patient-specific reasons why some children respond differently to treatment. We will analyse if age, sex, weight, height, creatinine clearance, ethnicity or genotype can predict a variation in treatment response. This could influence patient-specific treatment models in the future. We will also analyse the effect of concurrent medication used in the course of asthma treatment on our results. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients aged 1-15 years (inclusive) with acute severe asthma as defined by the BTS guidelines are eligible 2. About to receive / receiving IVS 3. ED cohort: Patients being admitted for acute asthma treatment in the Royal London Hospital or St Mary’s Hospital EDs while the research nurse is in attendance 4. CATS cohort: Patients being retrieved by the CATS team to Great Ormond Street Hospital or St Mary’s Hospital PICU over the study period.
|
|
E.4 | Principal exclusion criteria |
Patients being admitted to hospital for a primary reason other than asthma management will be excluded from the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure is a paediatric population PKPD model for salbutamol in acute severe asthma. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
PKPD modelling will be performed at the end of the trial |
|
E.5.2 | Secondary end point(s) |
Once PKPD modelling has been performed, we will analyse if age, sex, weight, height, creatinine clearance, ethnicity or genotype can predict a variation in treatment response. This will be performed at the final analysis. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Analysis at the end of the trial |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study is complete when 100 patients are recruited, or when 500 salbutamol assays have been collected if the study period allows. The trial is ended when the last recruited patient has been discharged from PICU. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 30 |